Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
Share Page
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts

Investor Overview

Corporate Profile
vTv Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.
Download Documentation Investor Presentation
Download Documentation AAIC 2016 Azeliragon Presentation
Get help downloading or viewing the above file types
Recent NewsMore >>
12/21/17vTv Therapeutics and Reneo Pharmaceuticals Enter Licensing Agreement for PPAR-Delta Program
HIGH POINT, N.C.--(BUSINESS WIRE)--Dec. 21, 2017-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into a global licensing agreement with Reneo Pharmaceuticals, a privately-held biotechnology company focused on developing treatments for orphan diseases. The agreement grants Reneo Pharmaceuticals exclusive worldwide rights to research, develop and commercialize vTv Therapeutics’ selective peroxisome ... 
Printer Friendly Version
12/21/17vTv Therapeutics Announces Licensing Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co. to Rights for vTv’s GLP-1r Agonist Diabetes Program in China and Other Pacific Rim Territories
HIGH POINT, N.C.--(BUSINESS WIRE)--Dec. 21, 2017-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into a licensing agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong Pharmaceutical”), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZSE: 000963.SZ), for rights to develop and commercialize vTv Therapeutics’ GLP-1r agonist program in China and other Pacific Rim count... 
Printer Friendly Version
11/13/17vTv to Host Key Opinion Leader Event to Discuss the Current State of Clinical Development in Alzheimer’s Disease
HIGH POINT, N.C.--(BUSINESS WIRE)--Nov. 13, 2017-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that the Company will host a key opinion leader (KOL) presentation and webcast focused on the current state of clinical development in Alzheimer’s disease in New York City on Thursday, November 16, 2017 from 8:00 am to 10:00 am ET. The event will feature two speakers, each with extensive experience in the clinical development in Alzheimer... 
Printer Friendly Version
11/08/17vTv Therapeutics Initiates Phase 1b/2 Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
As Part of Industry Partnership with JDRF HIGH POINT, N.C.--(BUSINESS WIRE)--Nov. 8, 2017-- vTv Therapeutics Inc. (Nasdaq: VTVT) announced today the initiation of simplici-T1, an adaptive Phase1b/2 study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of TTP399 in adult patients with type 1 diabetes (T1D). The study is designed to evaluate whether TTP399 is well tolerated when administered as an add-on to insulin the... 
Printer Friendly Version
There are currently no items available.
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever vTv Therapeutics Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed.